Drugs / M201-A
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT04464681 | Mar → Nov 2020 | — | Kitasato University | Completed | No outcome recorded |
| Phase 1 | NCT03055403 | Feb → Nov 2017 | — | Yuji KUMAGAI | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT04609059 | May → Oct 2019 | paroxysmal atrial fibrillation | Kitasato University | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | M201-A | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03055403 ↗ |
| Known as | M201-A hydrochloride | “single dose of M201-A hydrochloride or placebo 0.4 mg/kg” NCT04609059 ↗ |
| Route | Intravenous | “continuous intravenous injection” NCT03055403 ↗ |